Discounted Cash Flow Rating

Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Adaptimmune Therapeutics plc American Depositary Shares (ADAP)

Biological Products, (no Disgnostic Substances)

https://www.adaptimmune.com

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, non-small cell lung cancer, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.

60 JUBILEE AVENUE, MILTON PARK
ABINGDON, OXFORDSHIRE, X0

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/06/2015

Market Cap

263,491,823

Shares Outstanding

1,362,730,000

Weighted SO

227,121,597

Total Employees

N/A

Upcoming Earnings

08/12/2024

Similar Tickers

STOK --.--%

FIXX --.--%

BDTX --.--%

HARP --.--%

MREO --.--%

PIRS --.--%

PDSB --.--%

LPTX --.--%

AFMD --.--%

Beta

2.3010

Last Div

0.0000

Range

0.42-2.05

Chg

-0.0100

Avg Vol

2169608

Mkt Cap

263491823

Exch

NASDAQ

Country

GB

Phone

44 12 3543 0000

DCF Diff

1.7503

DCF

-0.0003

Div Yield

0.0000

P/S

1.8608

EV Multiple

-1.2771

P/FV

2.8672

Div Yield %

0.0000

P/E

-3.7897

PEG

-0.0849

Payout

0.0000

Current Ratio

3.0920

Quick Ratio

3.0920

Cash Ratio

2.5808

DSO

61.2566

DIO

0.0000

Op Cycle

61.2566

DPO

242.1737

CCC

-180.9171

Gross Margin

0.9200

Op Margin

-0.5873

Pretax Margin

-0.5499

Net Margin

-0.5144

Eff Tax Rate

0.0958

ROA

-0.2264

ROE

-1.1734

ROCE

-0.3470

NI/EBT

0.9354

EBT/EBIT

0.9364

EBIT/Rev

-0.5873

Debt Ratio

0.0940

D/E

0.3142

LT Debt/Cap

0.2058

Total Debt/Cap

0.2391

Int Coverage

159.6190

CF/Debt

-1.4669

Equity Multi

3.3415

Rec Turnover

5.9585

Pay Turnover

1.5072

Inv Turnover

0.0000

FA Turnover

2.2102

Asset Turnover

0.4402

OCF/Share

-0.1736

FCF/Share

-0.1823

Cash/Share

0.8404

OCF/Sales

-0.3133

FCF/OCF

1.0502

CF Coverage

-1.4669

ST Coverage

-8.3827

CapEx Coverage

-19.9025

Div&CapEx Cov

-19.9025

P/BV

2.8672

P/B

2.8672

P/S

1.8608

P/E

-3.7897

P/FCF

-5.6544

P/OCF

-6.2212

P/CF

-6.2212

PEG

-0.0849

P/S

1.8608

EV Multiple

-1.2771

P/FV

2.8672

DPS

0.0000

Latest Headlines (EST)

Zacks Investment Research Oct 27, 18:15 Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights Zacks Investment Research Oct 27, 18:15 Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights Zacks Investment Research Oct 27, 18:15 Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights Zacks Investment Research Oct 27, 18:15 Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights Zacks Investment Research Oct 27, 18:15 Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights Zacks Investment Research Oct 27, 18:15 Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights Zacks Investment Research Oct 27, 18:15 Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights Zacks Investment Research Oct 27, 18:15 Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights Zacks Investment Research Oct 27, 18:15 Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights Zacks Investment Research Oct 27, 18:15 Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights

Revenue Product Segmentation